Clinical Trial Update: A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating whether Secukinumab (Cosentyx) maintains remission in adults with non-radiographic axial spondyloarthritis. The trial is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-radiographic Axial Spondyloarthritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-radiographic Axial Spondyloarthritis | Phase 4 | Status: ACTIVE_NOT_RECRUITING